A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib

Relapsing multiple sclerosis

Annualized rate of new or enlarging T2 lesions (AR-NELT2) on MRI at Month 24 (relative to baseline MRI scan).

Participants with no evidence of disease activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6-month confirmed disability progression (6mCDP) and new/enlarging T2 lesions on MRI between baseline and Month 24., Adverse events, laboratory data, vital signs, electrocardiograms (ECGs), (Commercially confidential information)., Extension Part: Adverse events, laboratory data, vital signs, electrocardiogram (ECG), (Commercially confidential information)., Extension Part: - Annualized rate of new or enlarging T2 lesions on MRI - Participants with NEDA-3.

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Belgium, Denmark, France, Greece, Italy, Portugal, Slovakia, Spain